Betrixaban anticoagulant

Description Results NMA

Symptomatic pulmonary embolism during follow-up 0.79 [0.63; 0.99]

proximal deep-vein thrombosis 0.79 [0.63; 0.99]

Major bleeding during follow-up 1.19 [0.67; 2.12]

VTE 0.81 [0.65; 1.01]

Symptomatic deep vein thrombosis during follow-up 0.81 [0.65; 1.00]

net clinical benefit 0.83 [0.67; 1.02]

Venous thromboembolism or death 0.81 [0.65; 1.01]

betrixaban (at a dose of 80 mg once daily) for 35 to 42 days (n=3759)

vs.

subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10±4 days (n=3754)

double-blind

Parallel groups

Sample size: 3759/3754

Primary endpoint: asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism

FU duration: